These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 22841590

  • 1. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.
    Bezler M, Hengstler JG, Ullrich A.
    Mol Oncol; 2012 Oct; 6(5):516-29. PubMed ID: 22841590
    [Abstract] [Full Text] [Related]

  • 2. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
    O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ.
    Mol Cancer Ther; 2010 Jun; 9(6):1489-502. PubMed ID: 20501798
    [Abstract] [Full Text] [Related]

  • 3. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
    García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M.
    Clin Cancer Res; 2012 May 01; 18(9):2603-12. PubMed ID: 22407832
    [Abstract] [Full Text] [Related]

  • 4. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
    Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL.
    Clin Cancer Res; 2013 Feb 01; 19(3):610-9. PubMed ID: 23224399
    [Abstract] [Full Text] [Related]

  • 5. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T, Riccardi A, Mozzetti S, Ferlini C, Riccardi R.
    Int J Cancer; 2008 Dec 15; 123(12):2939-49. PubMed ID: 18803287
    [Abstract] [Full Text] [Related]

  • 6. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
    Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL.
    Cancer Res; 2013 Oct 01; 73(19):6013-23. PubMed ID: 23918797
    [Abstract] [Full Text] [Related]

  • 7. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
    Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, Kim P, Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, Baselga J, Scaltriti M.
    Sci Signal; 2014 Mar 25; 7(318):ra29. PubMed ID: 24667376
    [Abstract] [Full Text] [Related]

  • 8. Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.
    Sato Y, Yashiro M, Takakura N.
    Cancer Sci; 2013 Dec 25; 104(12):1618-25. PubMed ID: 24112719
    [Abstract] [Full Text] [Related]

  • 9. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
    Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL.
    Mol Cancer; 2014 Oct 24; 13():242. PubMed ID: 25344208
    [Abstract] [Full Text] [Related]

  • 10. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
    Lazrek Y, Dubreuil O, Garambois V, Gaborit N, Larbouret C, Le Clorennec C, Thomas G, Leconet W, Jarlier M, Pugnière M, Vié N, Robert B, Monnet C, Bouayadi K, Kharrat H, Mondon P, Pèlegrin A, Chardès T.
    Neoplasia; 2013 Mar 24; 15(3):335-47. PubMed ID: 23479511
    [Abstract] [Full Text] [Related]

  • 11. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
    Goltsov A, Faratian D, Langdon SP, Mullen P, Harrison DJ, Bown J.
    Cell Signal; 2012 Feb 24; 24(2):493-504. PubMed ID: 21996585
    [Abstract] [Full Text] [Related]

  • 12. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
    Brand TM, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL.
    Cancer Biol Ther; 2011 Sep 01; 12(5):436-46. PubMed ID: 21725209
    [Abstract] [Full Text] [Related]

  • 13. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
    Torka R, Pénzes K, Gusenbauer S, Baumann C, Szabadkai I, Őrfi L, Kéri G, Ullrich A.
    Neoplasia; 2014 Apr 01; 16(4):301-18. PubMed ID: 24862757
    [Abstract] [Full Text] [Related]

  • 14. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
    Qi W, Cooke LS, Stejskal A, Riley C, Croce KD, Saldanha JW, Bearss D, Mahadevan D.
    BMC Cancer; 2009 May 11; 9():142. PubMed ID: 19432987
    [Abstract] [Full Text] [Related]

  • 15. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
    Gayle SS, Arnold SL, O'Regan RM, Nahta R.
    Anticancer Agents Med Chem; 2012 Feb 11; 12(2):151-62. PubMed ID: 22043997
    [Abstract] [Full Text] [Related]

  • 16. Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation.
    Zhao Z, Li R, Sha S, Wang Q, Mao W, Liu T.
    Cancer Biol Ther; 2014 Oct 11; 15(10):1404-12. PubMed ID: 25046105
    [Abstract] [Full Text] [Related]

  • 17. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.
    Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL.
    Proc Natl Acad Sci U S A; 2011 Mar 22; 108(12):5021-6. PubMed ID: 21385943
    [Abstract] [Full Text] [Related]

  • 18. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS, Kang JC, Kim D, Ober RJ, Ward ES.
    Int J Cancer; 2015 Jul 15; 137(2):267-77. PubMed ID: 25471734
    [Abstract] [Full Text] [Related]

  • 19. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM, Sassi F, Catalano I, Torri V, Migliardi G, Zanella ER, Throsby M, Bertotti A, Trusolino L.
    Clin Cancer Res; 2015 Dec 15; 21(24):5519-31. PubMed ID: 26296355
    [Abstract] [Full Text] [Related]

  • 20. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
    Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX.
    Cancer Cell; 2009 May 05; 15(5):429-40. PubMed ID: 19411071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.